Knight W A, O'Bryan R M, Samal B, Costanzi J J
Invest New Drugs. 1984;2(1):71-3. doi: 10.1007/BF00173789.
The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with metastatic breast cancer. Among 72 fully and partial evaluable patients, one complete and four partial responses were seen. Toxicity was similar to other trials with this compound except for thrombocytopenia which was more frequent and severe and probably related to tumor infiltrating marrow. In addition, one patient experienced recall dermatitis following methyl-GAG. This toxicity has not been previously reported with this compound. Methyl-GAG has minimal activity at this dose and schedule among heavily pretreated patients with breast cancer.
西南肿瘤协作组对转移性乳腺癌患者每周使用甲基甘氨酸铝进行了评估。在72例可完全或部分评估的患者中，观察到1例完全缓解和4例部分缓解。除血小板减少症外，毒性与该化合物的其他试验相似，血小板减少症更频繁、更严重，可能与肿瘤浸润骨髓有关。此外，1例患者在使用甲基甘氨酸铝后出现回忆性皮炎。此前尚未有关于该化合物出现这种毒性的报道。在接受过大量治疗的乳腺癌患者中，按此剂量和疗程使用甲基甘氨酸铝活性极小。
